Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313355937> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4313355937 endingPage "120.13" @default.
- W4313355937 startingPage "120.13" @default.
- W4313355937 abstract "Abstract ALT-803 is a fusion protein complex consisting of IL-15N72D superagonist and a dimeric IL-15 receptor alpha (IL-15Rα) sushi domain IgG1 Fc fusion protein. When administered to mice, ALT-803 is capable of inducing NK and CD8+ T cell proliferation and activation, as well as potent antitumor responses. ALT-803 is currently in clinical studies using an intravenous (iv) route of administration. We were interested in exploring treatment regimens using subcutaneous (sc) administration of ALT-803 as an alternative to iv administration in order to lessen the adverse side effects that were observed. In this study, we compared the pharmacokinetics, immunostimulation, and anti-tumor efficacy of iv and sc administration of ALT-803 in C57BL/6 mice. We found the half-life of ALT-803 to be 7.5 hrs for iv administration vs. 7.7 hrs for sc. The maximal detected serum concentration of ALT-803 was 495 ng/ml at 16 hr time point following sc administration or 3926 ng/ml at 0.5 hr time point following iv administration. Similar bio-distribution of radio-labeled ALT-803 in mice was observed using quantitative PET-scan studies. We also demonstrated that ALT-803 administered iv or sc induced comparable proliferation of CD8+ T cells and NK cells and similarly activated immune cells which resulted in the reduction of tumor burden. A toxicity study of mice receiving multiple injections of ALT-803 for 4 weeks by iv or sc administration revealed that comparable immune system-related changes were observed and ALT-803 was well tolerated. The gradual absorbance into blood stream and lower maximal blood level of ALT-803 in sc injected mice, along with similar antitumor efficacy supports the use of ALT-803 by sc administration in patients with metastatic malignancies." @default.
- W4313355937 created "2023-01-06" @default.
- W4313355937 creator A5032881324 @default.
- W4313355937 creator A5038822639 @default.
- W4313355937 creator A5048735143 @default.
- W4313355937 creator A5052355681 @default.
- W4313355937 creator A5059906816 @default.
- W4313355937 creator A5066424143 @default.
- W4313355937 creator A5069160791 @default.
- W4313355937 creator A5085412582 @default.
- W4313355937 creator A5091378221 @default.
- W4313355937 date "2017-05-01" @default.
- W4313355937 modified "2023-09-23" @default.
- W4313355937 title "Biological Activities of IL-15 superagonist - IL-15 Mutein:IL-15RaFc complex following Intravenous or Subcutaneous Administration" @default.
- W4313355937 doi "https://doi.org/10.4049/jimmunol.198.supp.120.13" @default.
- W4313355937 hasPublicationYear "2017" @default.
- W4313355937 type Work @default.
- W4313355937 citedByCount "0" @default.
- W4313355937 crossrefType "journal-article" @default.
- W4313355937 hasAuthorship W4313355937A5032881324 @default.
- W4313355937 hasAuthorship W4313355937A5038822639 @default.
- W4313355937 hasAuthorship W4313355937A5048735143 @default.
- W4313355937 hasAuthorship W4313355937A5052355681 @default.
- W4313355937 hasAuthorship W4313355937A5059906816 @default.
- W4313355937 hasAuthorship W4313355937A5066424143 @default.
- W4313355937 hasAuthorship W4313355937A5069160791 @default.
- W4313355937 hasAuthorship W4313355937A5085412582 @default.
- W4313355937 hasAuthorship W4313355937A5091378221 @default.
- W4313355937 hasConcept C112705442 @default.
- W4313355937 hasConcept C167672396 @default.
- W4313355937 hasConcept C197934379 @default.
- W4313355937 hasConcept C203014093 @default.
- W4313355937 hasConcept C71924100 @default.
- W4313355937 hasConcept C8891405 @default.
- W4313355937 hasConcept C98274493 @default.
- W4313355937 hasConceptScore W4313355937C112705442 @default.
- W4313355937 hasConceptScore W4313355937C167672396 @default.
- W4313355937 hasConceptScore W4313355937C197934379 @default.
- W4313355937 hasConceptScore W4313355937C203014093 @default.
- W4313355937 hasConceptScore W4313355937C71924100 @default.
- W4313355937 hasConceptScore W4313355937C8891405 @default.
- W4313355937 hasConceptScore W4313355937C98274493 @default.
- W4313355937 hasIssue "1_Supplement" @default.
- W4313355937 hasLocation W43133559371 @default.
- W4313355937 hasOpenAccess W4313355937 @default.
- W4313355937 hasPrimaryLocation W43133559371 @default.
- W4313355937 hasRelatedWork W1982282930 @default.
- W4313355937 hasRelatedWork W2093168928 @default.
- W4313355937 hasRelatedWork W2141289501 @default.
- W4313355937 hasRelatedWork W2400119402 @default.
- W4313355937 hasRelatedWork W2594910449 @default.
- W4313355937 hasRelatedWork W2606334551 @default.
- W4313355937 hasRelatedWork W2960553615 @default.
- W4313355937 hasRelatedWork W2974708347 @default.
- W4313355937 hasRelatedWork W2991030316 @default.
- W4313355937 hasRelatedWork W3043458966 @default.
- W4313355937 hasVolume "198" @default.
- W4313355937 isParatext "false" @default.
- W4313355937 isRetracted "false" @default.
- W4313355937 workType "article" @default.